The role of serum and dietary advanced glycation endproducts in relation to cardiac function and structure: The Hoorn Study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Country of Publication: Netherlands NLM ID: 9111474 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1590-3729 (Electronic) Linking ISSN: 09394753 NLM ISO Abbreviation: Nutr Metab Cardiovasc Dis Subsets: MEDLINE
    • Publication Information:
      Publication: 2005- : Amsterdam : Elsevier
      Original Publication: [Heidelberg] : Springer International, c1991-
    • Subject Terms:
      Diet* ; Stroke Volume* ; Ventricular Function, Left*; Diabetes Mellitus, Type 2/*blood ; Glycation End Products, Advanced/*blood ; Ventricular Dysfunction, Left/*physiopathology; Aged ; Biomarkers/blood ; Diabetes Mellitus, Type 2/diagnosis ; Diabetes Mellitus, Type 2/epidemiology ; Echocardiography ; Female ; Heart Disease Risk Factors ; Humans ; Longitudinal Studies ; Male ; Middle Aged ; Netherlands/epidemiology ; Prevalence ; Risk Assessment ; Systole ; Time Factors ; Ventricular Dysfunction, Left/blood ; Ventricular Dysfunction, Left/diagnostic imaging ; Ventricular Dysfunction, Left/epidemiology
    • Abstract:
      Background and Aims: This study aims to investigate the relationship of serum and dietary advanced glycation endproducts (AGEs) with cardiac function and structure after eight years of follow-up.
      Methods and Results: We included 370 Hoorn Study participants (aged 66.4 ± 6.1, 47% women). Serum protein-bound AGEs [N ε -(carboxymethyl)lysine, N ε -(carboxyethyl)lysine, and pentosidine], as well as echocardiography to assess left atrium volume index (LAVI), left ventricle ejection fraction (LVEF), and left ventricle mass index (LVMI), were measured at baseline and after 8 years of follow-up. Dietary AGEs [N ε -(carboxymethyl)lysine and N ε -(carboxyethyl)lysine] were estimated at baseline with a validated food-frequency questionnaire and an AGEs database. Increased pentosidine [-1.4% (-2.6;-0.2)] and overall serum AGEs Z-scores over time [-2.1% (-3.8;-0.5)] were associated with decreased LVEF at follow-up, adjusted for confounders. Glucose metabolism status was an effect modifier (P-for-interaction = 0.04). In participants with impaired glucose metabolism, but not type 2 diabetes, increased pentosidine was associated with decreased LVEF [-4.2 (-8.0;-0.3)%]. Higher dietary N ε -(carboxyethyl)lysine [1.9 (0.1; 3.7)%] and overall dietary AGEs Z-scores [2.1 (0.1; 4.2)%] were associated with higher LVEF at follow-up. However, prior cardiovascular disease (CVD) was an effect modifier (P = 0.02). We found a stronger, non-significant, association of higher dietary (carboxyethyl)lysine with higher LVEF at follow-up in participants without CVD [2.3 (-0.1; 4.7)%] compared to participants with CVD [0.6 (-2.1; 3.4)%].
      Conclusion: Overall serum AGEs were longitudinally associated with impaired systolic function. Future research should focus on including changes in dietary AGEs intake over time and the relation of dietary AGEs with cardiac measures needs to be established in intervention studies using low AGEs diets.
      Competing Interests: Declaration of competing interest None declared.
      (Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.)
    • Contributed Indexing:
      Keywords: Advanced glycation endproducts; Echocardioghrapy; Epidemiology; Heart failure; Longitudinal cohort study
    • Accession Number:
      0 (Biomarkers)
      0 (Glycation End Products, Advanced)
    • Publication Date:
      Date Created: 20210914 Date Completed: 20211122 Latest Revision: 20211122
    • Publication Date:
      20231215
    • Accession Number:
      10.1016/j.numecd.2021.07.020
    • Accession Number:
      34518083